Linked Life Data

17845976

Source:http://linkedlifedata.com/resource/pubmed/id/17845976

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-9-11
pubmed:abstractText
Gemcitabine or Gemzar forms part of the class of the anti-cancer drugs antimetabolites. Gemcitabine is a structural analogue of the deoxycytidine with 2 fluorine atoms. There is a strong analogy between gemcitabine and cytosine arabinoside (Aracytine or Depocyt), at the same time structural, mechanistic and metabolic. However, if the intracellular derivatives triphosphate of gemcitabine seem more stable than those of the cytarabine, the two molecules move away from share their therapeutic activity. Indeed, if the cytosine arabinoside finds its place in the treatment of hematologic diseases, myeloblastic or lymphoblastic acute leukaemia and in acute myeloid leukaemias and myelodysplasy, gemcitabine sees its indications in the treatment of solid tumours such as non small cell lung cancer, adenocarcinoma of the pancreas, cancer of the bladder and metastatic breast cancer.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1769-6917
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
94 Spec No Actualites
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S85-9
pubmed:dateRevised
2009-11-11
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
pubmed:affiliation
Service de Pharmacologie, Centre René Huguenin, 35, rue Dailly, 92210 Saint-Cloud. lokiec@crh1.org
pubmed:publicationType
Journal Article, English Abstract, Review